Fast Facts: Multiple Myeloma and Plasma Cell Dyscrasias
Ramasamy, Karthik / Lonial, Sagar
Our understanding of multiple myeloma (MM) is growing at a formidable pace, particularly in terms of risk factors and potential drug targets. Minimal residual disease (MRD) negativity is set to become the new benchmark in treatment, and cytogenetic analysis is now paving the way for personalized therapies. This second edition of 'Fast Facts: Multiple Myeloma and Plasma Cell Dyscrasias' includes: - the new IMWG SLiM CRAB criteria - the latest a...